Hutchmed (China) Limited 24 May 2024 Press Release HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting Hong Kong, Shanghai...
Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by ...
Hutchmed (China) Limited 17 May 2024 HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board...
Hutchmed (China) Limited 17 May 2024 Press Release HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy...
Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it ...
Hutchmed (China) Limited 14 May 2024 Press Release HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab...
Hutchmed (China) Limited 14 May 2024 Press Release HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients...
Hutchmed (China) Limited 10 May 2024 Annual General Meeting held on May 10, 2024 - Poll Results Hong Kong, Shanghai, & Florham Park...
Hutchmed (China) Limited 08 May 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee ...
Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committe ...
Hutchmed (China) Limited 26 April 2024 HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal...
Hutchmed (China) Limited 22 April 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed (China) Limited 08 April 2024 2023 Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.